Geron (GERN) Change in Receivables (2024 - 2026)
Geron (GERN) posted Change in Receivables of $4.9 million for Q1 2026, up 209.75% sequentially from $1.6 million in Q4 2025, and up 205.27% YoY from $1.6 million in Q1 2025.
Geron (GERN) Change in Receivables (2024 - 2026) Analysis & Trends
Geron has reported Change in Receivables for 3 years, with the latest figure at $4.9 million in Q1 2026.
- Quarterly Change in Receivables rose 205.27% year-over-year to $4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.5 million (down 66.07% YoY) and the FY2025 annual result came in at $991000.0, down 97.22% from the prior year.
- Change in Receivables rose to $4.9 million in Q1 2026 per GERN's latest filing, from $1.6 million in the prior quarter.
- Over five years, Change in Receivables peaked at $27.1 million in Q3 2024 and troughed at -$4.6 million in Q1 2025.
- A 3-year average of $5.2 million and a median of $3.2 million in 2025 frame the typical range for Change in Receivables.
- The widest YoY moves for Change in Receivables: up 510.18% in 2025, down 104.69% in 2025.
- Over 3 years, Change in Receivables stood at $7.7 million in 2024, then plunged by 79.45% to $1.6 million in 2025, then soared by 209.75% to $4.9 million in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered $4.9 million, $1.6 million, and -$1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Geron | 1.02 Mn | -299.83 Mn | - | 8.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.94 Mn |
| Jun 30, 2026 | 8.94 Mn |
| Mar 31, 2026 | 4.89 Mn |
| Mar 31, 2026 | 4.89 Mn |
| Dec 31, 2025 | 1.58 Mn |
| Dec 31, 2025 | 1.58 Mn |
| Sep 30, 2025 | -1.27 Mn |
| Sep 30, 2025 | -1.27 Mn |
| Jun 30, 2025 | 5.33 Mn |
| Jun 30, 2025 | 5.33 Mn |
| Mar 31, 2025 | -4.65 Mn |
| Mar 31, 2025 | -4.65 Mn |
| Dec 31, 2024 | 7.69 Mn |
| Dec 31, 2024 | 7.69 Mn |
| Sep 30, 2024 | 27.13 Mn |
| Sep 30, 2024 | 27.13 Mn |
| Jun 30, 2024 | 874,000.00 |
| Jun 30, 2024 | 874,000.00 |